TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema
United States10 participantsStarted 2013-05
Plain-language summary
The purpose of this study is to determine whether an intravitreal dexamethasone implant (Ozurdex, Allergan) is effective to manage macular edema secondary to non-infectious uveitis.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Uveitis CME with central subfoveal thickness \> 350 microns
* non-infectious uveitis
* Visual Acuity \> 20/32
Exclusion Criteria:
* Visual Acuity worse than 20/200
* Moderate or severe glaucoma (as defined as \>2 topical ocular medications)
* Infectious uveitis
* Patients with active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis, vaccinia, varicella, mycobacterial infections, and fungal diseases.
* Aphakic eyes with rupture of the posterior lens capsule
* Anterior Chamber intraocular Lens and rupture of the posterior lens capsule
* Hypersensitivity to any components of the Ozurdex
What they're measuring
1
Best Corrected Visual Acuity (using Early Treatment Diabetic Retinopathy Study Protocal)
Timeframe: Day 90
Trial details
NCT IDNCT01870440
SponsorNorthern California Retina Vitreous Associates